(Q66038101)

English

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

clinical trial

In more languages

edit

Statements

instance of

clinical trial

0 references

title

A Phase 1 Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation (Take Rate) of a Cell-Cultured Smallpox Vaccine (CCSV) Compared to a Calf Lymph Vaccine (Dryvax®) (English)

0 references

medical condition

smallpox

0 references

country

United States of America

0 references

start time

March 2002

0 references

number of participants

350

0 references

clinical trial phase

phase I clinical trial

0 references

minimum age

18 year

0 references

maximum age

65 year

0 references

study type

interventional study

0 references

Identifiers

ClinicalTrials.gov ID

NCT00042094

0 references

(Q66038101)

Study of Reactogenicity, Safety, Immunogenicity, and Pock Lesion Formation of a Cell-Cultured Smallpox Vaccine Compared to Dryvax®

Statements

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)